Thu, 25 August 2016
Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.
Tue, 21 June 2016
CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed. Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.
Direct download: 01_Jennifer_Brown_02_What_is_the_significance_of_IGHV_mutations.mp4
Category:Blood-Cancers-Video -- posted at: 1:49pm PDT
Wed, 25 May 2016
Faculty member Dr. John Pagel, and an in-person audience of patients and caregivers joined GRACE for 'Not Your Father's CLL', webcast LIVE from Seattle, WA on April 22, 2016.
Dr. Pagel, Chief of the Hematologic Malignancies program for the expanded treatment and research of blood based cancers such as leukemia, multiple myeloma and lymphoma at Swedish Cancer Institute, spoke about current treatment options and the future of care, and took questions from both the in-person and online audiences. We invite you to watch the video.
Direct download: GRACEcast_-_Not_Your_Fathers_CLL_with_Dr._John_Pagel.mp4
Category:Blood-Cancers-Video -- posted at: 4:22pm PDT